Michael MacManus
@MP_MacManus
Followers
387
Following
912
Statuses
342
Radiation Oncologist, Researcher, aspiring musician. all views my own
Melbourne, Victoria
Joined December 2018
@gerryhanna @PeterMacCC @PeterMacRadOnc Thanks Gerry. Have been lucky to work with great people! @johnseymou
0
1
2
0
0
0
@TROGfightcancer @CancerVic First RCT to show advantage for RT plus systemic therapy vs RT alone in early stage low-grade follicular lymphoma. In addition to improved PFS also showed significant improvement in composite endpoint of risk of death or transformation to aggressive lymphoma.
0
0
1
1
0
3
0
0
0
@DrewMoghanaki @HegiFiona @EverittSJ @IJROBP @PeterMacRadOnc @sue However given uncertainty of estimating PFS in a merged international mixed cohort, OS is likely a more reliable outcome measure.
0
0
1
Terrific session on multimodality therapy in NSCLC at #wclc2024 Tantalising signals on potential role of induction chemoimmunotherapy before ChemoRT and even chemoimmunoRT before surgery. Thanks to discussant @gerryhanna for bringing clarity to a complex set of abstracts!
0
1
12
@gerryhanna @DrewMoghanaki @lcfamerica @AstraZeneca @DrAlexLouie @finn_corinne @DavidDbal @HegiFiona @drkevin_chua_lm @HoudaBahig @shalinivinod13 Could not agree more. It was a terrific session and a privilege to be there. Thanks for organising Drew!
0
0
2
Great presentation by @HegiFiona at the presidential session at #wclc2025 Compelling case for following best practice in lung cancer radiotherapy in clinical trials of radiation and systemic therapies. Timely staging and RT planning with PET, concurrent chemo and RT QA critical.
0
3
13
Great discussion at #WCLC24 by Dr Chee Lee of really exciting early phase data from studies of 2 new TKIs with activity in HER2 mutant NSCLC. High response rates and acceptable toxicity.
0
1
7
RT @ASTRO_org: In this new article from @MP_MacManus, Dose-response relationships between radiation exposure, bone marrow function as measu…
0
5
0
0
0
1
RT @PeterMacRadOnc: Our phenomenal #radonc team!! A superbly productive and energising day of aspirations and strategic planning @PeterMac…
0
7
0
0
0
3
1
0
1
@DrewMoghanaki @gerryhanna @finn_corinne @BTOGORG @FordePatrick @DrJNaidoo @Mat_Guc @fifimcdrmh @plumshea @alongi_filippo @AndrearicFili Agree. Volumes are contentious and dose should probably not be one size fits all. How to navigate the complexity of it all? Biology varies dramatically even within patients with similar histology. Challenging to design trials that take account of biology but are generalisable!
0
0
3